J Mov Disord.  2018 May;11(2):89-92. 10.14802/jmd.17082.

A Patient with Beta-Propeller Protein-Associated Neurodegeneration: Treatment with Iron Chelation Therapy

Affiliations
  • 1Divisions of Neurology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. limshenyang@gmail.com
  • 2The Mah Pooi Soo & Tan Chin Nam Centre for Parkinson's & Related Disorders, University of Malaya, Kuala Lumpur, Malaysia.
  • 3Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • 4Department of Neurology, University of Munich, Munich, Germany.
  • 5Divisions of Haematology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • 6Divisions of Neuroradiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Abstract

We present a case of beta-propeller protein-associated neurodegeneration, a form of neurodegeneration with brain iron accumulation. The patient harbored a novel mutation in the WDR45 gene. A detailed video and description of her clinical condition are provided. Her movement disorder phenomenology was characterized primarily by limb stereotypies and gait dyspraxia. The patient's disability was advanced by the time iron-chelating therapy with deferiprone was initiated, and no clinical response in terms of cognitive function, behavior, speech, or movements were observed after one year of treatment.

Keyword

Beta-propeller protein-associated neurodegeneration; neurodegeneration with brain iron accumulation; stereotypies; deferiprone

MeSH Terms

Brain
Chelation Therapy*
Cognition
Extremities
Gait Apraxia
Humans
Iron*
Movement Disorders
Iron
Full Text Links
  • JMD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr